Evidence map›Paper›PMID 31018669›Full record

ReviewCell transplantation2019

The Pros and Cons of Mesenchymal Stem Cell-Based Therapies.

Aleksandra Musiał-Wysocka, Marta Kot, Marcin Majka

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Cell transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 303 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
303citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04995081 phase2completednot on this mapstarted 2021, after this paper: background citation

A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease

TypeinterventionalSponsorHope Biosciences Research FoundationRan2021 to 2025Enrolled60ConditionsParkinson DiseaseArmsBiological/Vaccine: Allogeneic HB-adMSCs, Placebo
NCT05582226 naunknown statusnot on this mapstarted 2022, after this paper: background citation

A Randomized, Single Blinded Study of the Augmentation of Anterior Cruciate Ligament Reconstruction Using Stump-Derived Mesenchymal Stem Cells Versus Standard of Care Anterior Cruciate Ligament Reconstruction

TypeinterventionalSponsorAndrews Research & Education FoundationRan2022 to 2023Enrolled50ConditionsACL TearArmsACL reconstruction, Mesenchymal stem cell implantation
3 · Its place in the literature

Who cites it

303 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. The Biodistribution ofVeterinary sciences · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

243 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aleksandra Musiał-Wysocka1 Department of Transplantation, Jagiellonian University Medical College, Cracow, Poland.
Marta Kot1 Department of Transplantation, Jagiellonian University Medical College, Cracow, Poland.
Marcin Majka1 Department of Transplantation, Jagiellonian University Medical College, Cracow, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The need to search for new, alternative treatments for various diseases has prompted scientists and physicians to focus their attention on regenerative medicine and broadly understood cell therapies. Currently, stem cells are being investigated for their potentially widespread use in therapies for many untreatable diseases. Nowadays modern treatment strategies willingly use mesenchymal stem cells (MSCs) derived from different sources. Researchers are increasingly aware of the nature of MSCs and new possibilities for their use. Due to their properties, especially their ability to self-regenerate, differentiate into several cell lineages and participate in immunomodulation, MSCs have become a promising tool in developing modern and efficient future treatment strategies. The great potential and availability of MSCs allow for their various clinical applications in the treatment of many incurable diseases. In addition to their many advantages and benefits, there are still questions about the use of MSCs. What are the mechanisms of action of MSCs? How do they reach their destination? Is the clinical use of MSCs safe? These are the main questions that arise regarding MSCs when they are considered as therapeutic tools. The diversity of MSCs, their different clinical applications, and their many traits that have not yet been thoroughly investigated are sources of discussions and controversial opinions about these cells. Here, we reviewed the current knowledge about MSCs in terms of their therapeutic potential, clinical effects and safety in clinical applications.

Indexed as

Cell- and Tissue-Based TherapyHumansMesenchymal Stem Cell TransplantationRegenerative Medicineengraftmentimmunomodulatory propertiesmesenchymal stem cellssomatic cell therapytransplantation

Identifiers

PMID31018669
PMCPMC6719501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.